Ronald Mark Evans (born April 17, 1949 in Los Angeles, California) is an American Biologist, Professor and Head of the Salk’s Gene Expression Laboratory, and the March of Dimes Chair in Molecular and Developmental Biology at the Salk Institute for Biological Studies[1] in La Jolla, California and a Howard Hughes Medical Institute Investigator.
Nowadays, NRs are among the most widely investigated group of pharmaceutical targets in the world, already yielding benefits in drug discovery for cancer, muscular dystrophies, osteoporosis, type II diabetes, obesity, and cardiovascular diseases.
Members of the nuclear receptor (NR) superfamily of ligand-regulated transcription factors play important roles in reproduction, development, and physiology.
They are primary targets in breast, prostate, and pancreatic cancers and leukemia treatment and have therapeutic roles in chronic inflammation, osteoporosis, and type 2 diabetes and asthma.
His muscle metabolism studies led to the discovery of exercise mimetics, which promote the benefits of fitness without training and may help battle the obesity epidemic, diabetes, heart disease, and frailty.